La Dr. Alessandra Bigi si è laureata con il massimo dei voti e la lode in Biologia presso l'Università degli Studi di Firenze nel 2016. Ha conseguito il Dottorato di Ricerca in Scienze Biomediche presso il Dipartimento di Scienze Biomediche Sperimentali e Cliniche, Università degli Studi di Firenze, nel 2020. Durante il Dottorato le sue attività di ricerca hanno riguardato la relazione tra struttura e tossicità di aggregati proteici aberranti in malattie da deposizione proteica quali il morbo di Alzheimer (AD), il morbo di Parkinson (PD) e la sclerosi laterale amiotrofica (SLA). Dal 2020 al 2023 è stata Assegnista di Ricerca presso il Dipartimento di Scienze Biomediche Sperimentali e Cliniche dell'Università di Firenze. In questo periodo ha partecipato a numerosi progetti di ricerca volti allo studio dei pathways citotossici associati alle malattie da misfolding proteico, con l'obiettivo di identificare nuovi approcci diagnostici e terapeutici. Oggi è Ricercatrice (RTD-A) in Biochimica (SSD BIOS-07/A). Ha attualmente 23 pubblicazioni su riviste internazionali (JCR) e il suo indice h (Scopus) è 12. È membro della Società Italiana di Biochimica e Biologia Molecolare (SIB) dal 2017.
Alessandra Bigi, PhD
E-Mail: alessandra.bigi@unifi.it
Data di nascita: 23 Maggio 1990
Luogo di nascita: Arezzo, Italia
Aprile 2020 Dottorato di Ricerca in “Scienze Biomediche”, curriculum “Biologia Funzionale di Biomolecole e Biosistemi” con tesi dal titolo “ Study of the relationship between structure and toxicity of different α-synuclein aggregates and related cellular dysfunctions”. Relatore Prof. Cristina Cecchi. SSD: BIOS-07/A, ex BIO/10 – BIOCHIMICA. Dipartimento di Scienze Biomediche Sperimentali e Cliniche, Università degli Studi di Firenze, Italia.
Luglio 2016 Laurea Magistrale in Biologia (LM-6). Votazione finale: 110/110 con Lode e Complimenti della Commissione. Università degli Studi di Firenze, Italia.
Aprile 2013 Laurea Triennale in Scienze Biologiche (L-13). Votazione finale: 110/110. Università degli Studi di Firenze, Italia.
Luglio 2009 Diploma di Maturità Scientifica. Votazione finale: 100/100. Liceo Scientifico Francesco Redi, Arezzo, Italia.
01/02/2023 - Attuale Ricercatore (RTD-A) in Biochimica (SSD BIOS-07/A, ex BIO/10) presso il Dipartimento di Scienze Biomediche Sperimentali e Cliniche, Università degli Studi di Firenze, finanziato dal PNRR, Partenariato Esteso 8, Spoke 2, progetto Age-It, sotto la supervisione del Prof. Fabrizio Chiti.
01/03/2022 – 31/01/2023 Assegnista di Ricerca Post-dottorato presso il Dipartimento di Scienze Biomediche Sperimentali e Cliniche, Università degli Studi di Firenze. Progetto di Ricerca: “Trodusquemine as a new therapeutic molecule for amyotrophic lateral sclerosis”. Relatore Prof. Cristina Cecchi (SSD BIOS-07/A, ex BIO/10).
01/03/2021 – 28/02/2022 Assegnista di Ricerca Post-dottorato presso il Dipartimento di Scienze Biomediche Sperimentali e Cliniche, Università degli Studi di Firenze. Progetto di Ricerca: “Single domain antibodies as diagnostic and therapeutic tools for Alzheimer's disease”. Relatore Dr. Roberta Cascella (SSD BIOS-07/A, ex BIO/10).
01/03/2020 – 28/02/2021 Assegnista di Ricerca Post-dottorato presso il Dipartimento di Scienze Biomediche Sperimentali e Cliniche, Università degli Studi di Firenze. Progetto di Ricerca: “Functional characterization of full-length TDP-43 in the pathogenesis of amyotrophic lateral sclerosis”. Relatori Prof. Cristina Cecchi e Prof. Fabrizio Chiti (SSD BIOS-07/A, ex BIO/10).
01/11/2016 - 31/10/2019 Studentessa di Dottorato in “Scienze Biomediche” presso il Dipartimento di Scienze Biomediche Sperimentali e Cliniche, Università degli Studi di Firenze. Relatore Prof. Cristina Cecchi (SSD BIOS-07/A, ex BIO/10).
2023 - Ad oggi Università degli Studi di Firenze - Corso di Laurea Triennale in Infermieristica, Scuola di Scienze della Salute Umana, Università degli Studi di Firenze - Insegnamento B030209 - SCIENZE BIOMOLECOLARI - BIOCHIMICA, 1 CFU (SSD BIOS-07/A, già BIO/10).
2023 - Ad oggi Università degli Studi di Firenze - Corso di Laurea Magistrale in Biotecnologie Mediche e Farmaceutiche - Insegnamento B029492 – TECNICHE DI BIOCHIMICA STRUTTURALE E CELLULARE, 1 CFU (SSD BIOS-07/A, già BIO/10).
2020 Nomina a Cultore della Materia in Biochimica (SSD BIOS-07/A, già BIO/10) per il Corso di Laurea Triennale (DM 270/04) in Infermieristica, Scuola di Scienze della Salute Umana, Università degli Studi di Firenze. Titolare del corso Prof. Cristina Cecchi.
2017 - Ad oggi Attività di tutoraggio per studenti di laurea triennale e magistrale in Scienze Biologiche e Biotecnologie durante il loro tirocinio sperimentale sotto la supervisione della Prof.ssa Cristina Cecchi e del Prof. Fabrizio Chiti presso il Dipartimento di Scienze Biomediche Sperimentali e Cliniche, Università degli Studi di Firenze.
2024 FEBS Open Bio Poster Prize al 48° Congresso FEBS (Federation of European Biochemical Societies) “Mining Biochemistry for Human Health and Well-Being”, Milano (Italia), 29 Giugno - 3 Luglio 2024.
2024 Borsa SIB (Società Italiana di Biochimica) per l'iscrizione al 48° Congresso FEBS “Mining Biochemistry for Human Health and Well-Being”, Milano (Italia), 29 Giugno - 3 Luglio 2024.
2022 “FEBS Bursary” (€ 680) per la partecipazione all'IUBMB-FEBS-PABMB 2022 Congress “The Biochemistry global summit”, Lisbona (Portogallo), 9-14 Luglio 2022.
2021 Poster Prize al 61° Congresso SIB 2021 (interamente virtuale), 23-24 Settembre 2021, per la presentazione dell'abstract “Diagnostic and therapeutic potential of single-domain antibodies in Alzheimer’s disease”.
2024 Bigi A, Chiti F. “Modelling the aging-associated loss of proteostasis leading to proteinopathy”. PNRR Age-It “Ageing well in an ageing society” 1° Incontro Generale del Programma, Venezia (Italia), 20-22 Maggio 2024.
2022 Bigi A, Cascella R, Ermini E, Barbut D, Zasloff M, Chiti F, Cecchi C. “Mechanistic insights into the protective role of trodusquemine in TDP-43-associated proteinopathies”. TUM Congress 2022, Perugia (Italia), 1 Dicembre 2022, organizzato dalla sottosezione Toscana Umbria Marche (TUM) della Società Italiana di Biochimica.
2022 Bigi A, Cascella R, Lombardo E, Barbut D, Zasloff M, Chiti F, Cecchi C. “Trodusquemine prevents TDP-43 inclusion formation and suppresses its toxicity in vitro and in vivo”. Presentazione orale “on demand” caricata sulla piattaforma virtuale della “Hybrid AD/PD™ 2022, Alzheimer’s & Parkinson’s Diseases Conference” – Barcellona (Spagna), 15-20 Marzo 2022.
2021 Bigi A, Napolitano L. Vadukul D, Aprile FA, Chiti F, Cecchi C, Cascella R. “Diagnostic and therapeutic potential of single domain antibodies in Alzheimer’s disease”. “SIB 2021 61° Congresso”, 23-24 Settembre 2021.
2019 Bigi A, Cascella R, Chen SW, De Simone A, Dobson CM, Chiti F, Cecchi C. Molecular basis of neuronal calcium dyshomeostasis caused by α-synuclein aggregates in Parkinson’s disease. “SIB 2019 60° Congresso” Lecce (Italia), 18-20 Settembre 2019.
2017 Bigi A, Evangelisti E, Stefani M, Chiti F, Cecchi C, Cascella R. A$beta$42 oligomers interact with GM1 ganglioside inducing neuronal calcium overload. “SIB 2019 59° Congresso” Caserta (Italia), 20-22 Settembre 2017.
2025 Fondi di Ateneo (RICATEN) - Università degli Studi di Firenze. Titolo del Progetto: hallmarks of aging: DNA damage, telomere dysfunction, loss of proteostasis, and the search continues. Principal Investigator.
1. Bigi A, Panzi A, Ermini E, Cascella R, Cecchi C, Chiti F. Neuronal models of the aging-associated loss of proteostasis leading to proteinopathy. Accepted abstract. The research will be presented as a poster at the AD/PD™ 2025 Alzheimer's & Parkinson's Diseases Conference that will be held in Vienna (Austria) on April 1-5, 2025.
2. Cecchi C, Bigi A, Ermini E, Gennari M, Banchelli M, Staderini T, Barbut D, Zasloff M, Chiti F, Cascella R. Trodusquemine prevents the formation of TDP-43 inclusions and their associated neurotoxicity. Accepted abstract. The research will be presented as a poster at the AD/PD™ 2025 Alzheimer's & Parkinson's Diseases Conference that will be held in Vienna (Austria) on April 1-5, 2025.
3. Ristori S, Bientinesi E, Bigi A, Monti D. Effects of Aβ oligomers on human astrocytes from healthy subjects and Alzheimer’s disease patients. SIPMeT 2024 Translational Pathophysiology Congress. September 19-21, 2024; Udine (Italy).
4. Bigi A, Ermini E, Cascella R, Cecchi C, Chiti F. Modelling the aging-associated loss of proteostasis leading to proteinopathy. 48th FEBS Congress “Mining Biochemistry for Human Health and Well-Being”. June 29th - July 3rd, 2024; Milano (Italy).
5. Cascella R, Bigi A, Ermini E, Staderini T, Conti AC, Banchelli M, Barbut D, Zasloff M, Chiti F, Cecchi C. Targeting the insoluble inclusions of TDP-43 by trodusquemine as a potential therapeutic strategy for ALS and FTLD. 48th FEBS Congress “Mining Biochemistry for Human Health and Well-Being”, June 29th - July 3rd. 2024; Milano (Italy).
6. Bientinesi E, Ristori S, Bigi A, Cecchi C, Chiti F, Monti D. Different effects of Aβ oligomers on human astrocytes from healthy subjects and Alzheimer’s disease patients. PNRR Age-It “Ageing well in an ageing society” 1st General Meeting of the Programme. May 20-22, 2024; Venezia (Italy).
7. Tenori L, Vignoli A, Neri L, Bigi A, Chiti F. Metabolomic investigation of the effects of Alzheimer’s molecular stressors on neuroblastoma cells. PNRR Age-It “Ageing well in an ageing society” 1st General Meeting of the Programme. May 20-22, 2024; Venezia (Italy).
8. Ristori S, Bientinesi E, Bigi A, Lulli M, Monti D. Astrocyte senescence as a general mechanism underlying sex differences in Alzheimer’s disease onset. SIPMeT Young Scientists Meeting 2023 “General pathology: the trunk of the tree of medicine”. September 22-23, 2023; Parma (Italy).
9. Bigi A, Fani G, Bessi V, Napolitano L, Neri L, Cascella R, Matteini P, Cecchi C, Chiti F. Novel promising CSF biomarkers of Alzheimer’s disease based on protein misfolding, protein aggregation and proteotoxicity. 62° SIB Congress – 2023. September 7-9, 2023; Firenze (Italy).
10. Napolitano L, Bigi A, Vadukul D, Aprile F, Chiti F, Cecchi C, Cascella R. Single domain antibodies as promising tools for the selective detection and neutralization of neurotoxic Aβ42 oligomers in the cerebrospinal fluid of Alzheimer’s disease patients. Alzheimer’s Association International Conference® 2023 (AAIC®), July 16-20, 2023; Amsterdam (Netherlands).
11. Bigi A, Cascella R, Ermini E, Staderini T, Barbut D, Zasloff M, Chiti F, Cecchi C. Trodusquemine: a promising therapeutic molecule for TDP-43-associated proteinopathies. AD/PD™ 2023, Alzheimer's & Parkinson's Diseases Conference. March 28th – April 1st, 2023; Gothemburg (Sweden).
12. Napolitano L, Bigi A, Vadukul D, Aprile FA, Chiti F, Cecchi C, Cascella R. Neurotoxic Aβ42 oligomers can be selectively detected and neutralized by single domain antibodies. AD/PD™ 2023, Alzheimer's & Parkinson's Diseases Conference. March 28th – April 1st, 2023; Gothemburg (Sweden).
13. Staderini T, Bigi A, Mongiello D, Chiti F. Phase separation of Full Length recombinant TAR DNA-Binding Protein (FL TDP43). AriSLA Meeting 2022 - Research, development and innovation in ALS. November 3-4, 2022; Milano (Italy).
14. Staderini T, Bigi A, Mongiello D, Chiti F. Phase separation of Full Length recombinant TAR DNA-Binding Protein (FL TDP43). The Leuven Protein Aggregation Meeting. September 21-23, 2022; Leuven (Belgium).
15. Bigi A, Cascella R, Ermini E, Barbut D, Zasloff M, Chiti F, Cecchi C. Insights into the protective role of natural aminosterols in TDP-43-associated proteinopathies. IUBMB–FEBS–PABMB Congress 2022- The Biochemistry global summit. July 9-14, 2022; Lisbon (Portugal).
16. Staderini T, Bigi A, Mongiello D, Chiti F. Biophysical characterization of Full Length recombinant TAR DNA-Binding Protein (FL TDP43) phase separation and aggregation. IUBMB–FEBS–PABMB Congress 2022 – The Biochemistry global summit. July 9-14, 2022; Lisbon (Portugal).
17. Napolitano L, Bigi A, Vadukul D, Aprile FA, Chiti F, Cecchi C, Cascella R. Single domain antibodies as new detectors of neurotoxic Aβ42 oligomers. Alzheimer's Association International Conference 2022. July 31 – August 4, 2022; San Diego, CA (USA).
18. Napolitano L, Bigi A, Vadukul D, Aprile FA, Chiti F, Cecchi C, Cascella R. Selective targeting of neurotoxic Aβ42 oligomers by single domain antibodies. AD/PD™ 2022, Alzheimer's & Parkinson's Diseases Conference. March 15-20, 2022; Barcelona (Spain).
19. Cascella R, Bigi A, Lombardo E, Barbut D, Zasloff M, Chiti F, Cecchi C Therapeutic effects of Trodusquemine in amyotrophic lateral sclerosis. 61° SIB 2021 Congress. Virtual edition. September 23-24, 2021.
20. Bigi A, Napolitano L, Vadukul D, Aprile FA, Chiti F, Cecchi C, Cascella R. Diagnostic and therapeutic potential of single domain antibodies in Alzheimer’s disease. 61° SIB 2021 Congress. Virtual edition. September 23-24, 2021. Poster and oral presentation.21. Bigi A, Cascella R, Loffredo G, Chiti F, Cecchi C. Targeting pathological amyloid aggregates with antibodies. AAT-AD/PD™ 2020, Alzheimer's & Parkinson's Diseases Conference Focus Meeting (entirely virtual). 2-5 April, 2020.
22. Cascella R, Bigi A, Moretti M, Cecchi C, Chiti F. Functional characterisation of TDP-43 in the pathogenesis of amyotrophic lateral sclerosis. AAT-AD/PD™ 2020, Alzheimer's & Parkinson's Diseases Conference Focus Meeting (entirely virtual). 2-5 April, 2020.
23. Bigi A, Cascella R, Moretti M, Chiti F, Cecchi C. The impairment of autophagy-lysosomal pathway in TDP-43 associated diseases. The European Conference on Recent Advances in Lysosomal Diseases (Med-Lysosomal). October 24-25, 2019; London (UK).
24. Bigi A, Cascella R, Chen S.W., De Simone A, Dobson CM, Chiti F, Cecchi C. Molecular basis of neuronal calcium dyshomeostasis caused by α-synuclein aggregates in Parkinson’s disease. SIB 2019 60° Congress. September 18-20, 2019; Lecce (Italy). Poster and short oral presentation.
25. Bigi A, Cascella R, Chen SW, De Simone A, Dobson CM, Chiti F, Cecchi C. The mechanism of neurotoxicity associated with α-synuclein aggregation. 44th FEBS Congress “From molecules to living systems”. July 6-11, 2019; Krakow (Poland).
26. Capitini C, Bigi A, Cascella R, Maggi L, Cecchi C, Pavone F, Calamai M. Effect of cholesterol on the proteolytic processing of APP and protein dynamics in living cells. AD/PD™ 2019, Alzheimer's & Parkinson's Diseases Conference. March 26-31, 2019; Lisbon (Portugal).
27. Cascella R, Bigi A, Chen SW, Fusco G, Perni M, De Simone A, Dobson CM, Chiti F, Cecchi C. Targeting the toxicity of α-synuclein oligomers by antibodies. AD/PD™ 2019, Alzheimer's & Parkinson's Diseases Conference. March 26-31, 2019; Lisbon (Portugal).
28. Bigi A, Cascella R, Fani G, Bruno M, Bernacchioni C, Cencetti F, Chiti F, Donati C, Cecchi C. Bioactive lipids rescue neuronal degeneration induced by amyloid beta oligomers. AD/PD™ 2019, Alzheimer's & Parkinson's Diseases Conference. March 26-31, 2019; Lisbon (Portugal).
29. Capitini C, Bigi A, Cascella R, Cecchi C, Pavone F, Calamai M. Investigation of the APP, BACE1 and ADAM10 dynamics on the plasma membrane by single molecule tracking experiments. ASCB/EMBO Annual Meeting, December 8-12, 2018; San Diego (CA, USA).
30. Cascella R, Bigi A, Chen SW, Cremades N, Dobson CM, Chiti F, Cecchi C. The mechanism of neuronal toxicity by oligomers and fibrils of α-synuclein. FISV 2018. September 19-20, 2018, Roma (Italy).
31. Bigi A, Cascella R, Chen SW, Fusco G, De Simone A, Dobson CM, Chiti F, Cremades N, Cecchi C. Molecular basis of neuronal toxicity by alfa-synuclein oligomers and fibrils. AAT-AD/PD™ 2018, Alzheimer's & Parkinson's Diseases Conference Focus Meeting, March 15-18, 2018; Torino (Italy).
2025 Membro del comitato organizzatore del Congresso SIB-TUM 2025 che si terrà a Firenze (Italia) il 9 giugno 2025 (sito web del meeting: http://bioserver2.sbsc.unifi.it/SibTUM/SIB.html).
Dal 2023 Editor per Frontiers in Neuroscience (sito web del tema di ricerca: https://www.frontiersin.org/research-topics/55791/promising-therapeutic-strategies-for-alzheimers-disease-a-focus-on-amyloid--targeting).
Dal 2019 Revisore per Advanced Science, Alzheimers Research and Therapy, Biochemical and biophysical research communications, Biomedicines, Cell & bioscience, Cells, Cellular and Molecular Life Sciences, International journal of biological macromolecules, International Journal of Molecular Sciences, Metabolic brain disease, Neurochemistry international, Pharmaceuticals, Pharmaceutics, Review Commons. L'attività di revisione paritaria è consultabile sulla pagina ORCID 0000-0002-1067-6288.
2022 Corso di formazione di 4 ore sui rischi derivanti dall'uso di gas criogenici – Università degli Studi di Firenze (Italia).
2021 Corso di formazione di 5 ore sulla manipolazione sicura di sorgenti radioattive non sigillate – Università degli Studi di Firenze (Italia).
Madrelingua Italiano
Altre lingue Inglese: ottime capacità di lettura, scrittura e conversazione.
Francese: buone capacità di lettura, scrittura e conversazione.
Gli interessi di ricerca della Dr. Alessandra Bigi riguardano lo studio della relazione tra struttura e tossicità di aggregati proteici aberranti coinvolti in malattie da misfolding proteico (morbo di Alzheimer, morbo di Parkinson, sclerosi laterale amiotrofica) con l'obiettivo di identificare potenziali biomarcatori e molecole terapeutiche per il loro trattamento.
Legenda
Dr. Alessandra Bigi graduated with highest marks et encomium in Biology at the University of Florence in 2016. She obtained the PhD in Biomedical Sciences at the Department of Experimental and Clinical Biomedical Sciences, University of Florence, in 2020. During the PhD her research activities concerned the relationship between structure and toxicity of aberrant protein aggregates in protein deposition diseases such as Alzheimer’s disease (AD), Parkinson’s Disease (PD) and amyotrophic lateral sclerosis (ALS). She has been Postdoctoral Research fellow (Assegnista di Ricerca) at the Department of Experimental and Clinical Biomedical Sciences, University of Florence, from 2020 to 2023. In this period, she has been involved in several research projects focused on the study of the cytotoxic pathways associated with protein misfolded diseases, with the aim to identify novel diagnostic and therapeutic approaches against age-associated pathologies. Today she is a Researcher (RTD-A) in Biochemistry (SSD BIO/10).She has 23 international publications (JCR) and her h index (Scopus) is 11. She is a member of the Italian Society of Biochemistry and Molecular Biology (SIB) since 2017.
Education and training
April 2020
PhD in “Biomedical Sciences”, curriculum “Functional Biology of Biomolecules and Biosystems” with a thesis entitled “Study of the relationship between structure and toxicity of different α-synuclein aggregates and related cellular dysfunctions”. Supervisor Prof. Cristina Cecchi.
Department of Experimental and Clinical Biomedical Sciences, University of Florence, Italy.
July 2016
Master’s Degree in Biology (LM-6). Final mark: 110/110 cum laude and Complimenti della Commissione
University of Florence, Italy.
April 2013
Bachelor’s Degree in Biological Sciences (L-13). Final mark: 110/110
July 2009
Scientific High School Diploma. Final mark: 100/100
Liceo Scientifico Francesco Redi, Arezzo, Italy.
Research experience
01/02/2023 - Present
Researcher (RTD-A) in Biochemistry (SSD BIO/10), at the Department of Experimental and Clinical Biomedical Sciences, University of Florence.
01/03/2022 - 31/01/2023
Postdoctoral Research Fellow at the Department of Experimental and Clinical Biomedical Sciences, University of Florence.
Research Project: “Trodusquemine as a new therapeutic molecule for amyotrophic lateral sclerosis”. Supervisor Prof. Cristina Cecchi.
01/03/2021 –28/02/2022
Research Project: “Single domain antibodies as diagnostic and therapeutic tools for Alzheimer's disease”. Supervisor Dr. Roberta Cascella.
01/03/2020 – 28/02/2021
Research Project: “Functional characterization of full-lenght TDP-43 in the pathogenesis of amyotrophic lateral sclerosis”. Supervisors Prof. Cristina Cecchi and Prof. Fabrizio Chiti.
01/11/2016 - 31/10/2019
PhD student in “Biomedical Sciences” at the Department of Experimental and Clinical Biomedical Sciences, University of Florence. Supervisor Prof. Cristina Cecchi.
Professional Membership
2017 - Present
Member of the Italian Society of Biochemistry and Molecular Biology (SIB).
Honours
FEBS Open Bio Poster Prize at the 48th FEBS Congress “Mining Biochemistry for Human Health and Well-Being”, Milano (Italy), June 29th - July 3rd, 2024.
2021
Poster Prize at the “SIB 2021 61° Congress” (entirely virtual), September, 23-24, 2021, for presenting the abstract “Diagnostic and therapeutic potential of single-domain antibodies in Alzheimer’s disease”.
Selected speaker at national and international conferences
2024
2022
Bigi A, Cascella R, Ermini E, Barbut D, Zasloff M, Chiti F, Cecchi C. “Mechanisticinsights into the protective role of trodusquemine in TDP-43-associated proteinopathies”. TUM Congress 2022, Perugia (Italy), December 1st, 2022.
Bigi A, Cascella R, Lombardo E, Barbut D, Zasloff M, Chiti F, Cecchi C. “Trodusquemine prevents TDP-43 inclusion formation and suppresses its toxicity in vitro and in vivo”. Oral “on demand” uploaded in the virtual Conference platform of the “Hybrid AD/PD™ 2022, Alzheimer’s & Parkinson’s Diseases Conference” – Barcelona (Spain), March 15-20, 2022.
Bigi A, Napolitano L. Vadukul D, Aprile FA, Chiti F, Cecchi C, Cascella R. “Diagnostic and therapeutic potential of single domain antibodies in Alzheimer’s disease”. “SIB 2021 61° Congress” (entirely virtual) September 23-24, 2021 (poster and short oral presentation).
2019
Bigi A, Cascella R, Chen SW, De Simone A, Dobson CM, Chiti F, Cecchi C. Molecular basis of neuronal calcium dyshomeostasis caused by α-synuclein aggregates in Parkinson’s disease. “SIB 2019 60° Congress” Lecce (Italy), September 18-20, 2019 (poster and short oral presentation).
2017
Bigi A, Evangelisti E, Stefani M, Chiti F, Cecchi C, Cascella R. Aβ42 oligomers interact with GM1 ganglioside inducing neuronal calcium overload. “SIB 2019 59° Congress” Caserta (Italy), September 20-22, 2017.
Other scientific activities
Since 2019
Reviewer for Neural Regeneration Research, Biomedicines, Cellular and Molecular Life Sciences, Cells, International Journal of Molecular Sciences, Pharmaceutics, Review Commons, Scientific Reports, Pharmaceuticals, Neurochemistry International, BBA - Molecular Cell Research.
The research interests of Dr. Alessandra Bigi focus on the study of the relationship between structure and toxicity of aberrant protein aggregates involved in protein misfolded diseases (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis) with the aim to identify potential biomarkers and therapeutic molecules for their treatment.
